Kura Oncology, Inc.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company developing and commercializing targeted medicines for cancer and other diseases. Its first commercial product, KOMZIFTI (ziftomenib), is an oral menin inhibitor approved in the United States for adults with relapsed or refractory acute myeloid leukemia… From the company’s description.
In fiscal 2025, Kura Oncology, Inc. reported revenue of $67.48M, up 25.2% from fiscal 2024, and a net loss of $278.67M. Its operating margin was −449.9%, and operations used $64.06M in cash. Over the twelve months to Jun 30, 2026, revenue was $77.22M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kura Oncology, Inc. does
In the company’s own words
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company developing and commercializing targeted medicines for cancer and other diseases. Its first commercial product, KOMZIFTI (ziftomenib), is an oral menin inhibitor approved in the United States for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation and no satisfactory alternative treatment options. Kura also evaluates ziftomenib in clinical trials for other AML settings and gastrointestinal stromal tumors, and develops next-generation menin inhibitors for cardiometabolic disorders and solid tumors. Its pipeline includes darlifarnib, a farnesyl transferase inhibitor being studied in combination with targeted therapies for solid tumors, including renal cell, lung, colorectal and pancreatic cancers. Kura commercializes KOMZIFTI in the United States with Kyowa Kirin, which handles commercialization outside the country. The company was founded in 2014 and has developed from a research and development business into a commercial-stage organization. KOMZIFTI U.S. sales began in November 2025. Its website is www.kuraoncology.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1422143
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kura Oncology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kura Oncology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kura Oncology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kura Oncology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kura Oncology, Inc.'s last four quarterly filings that the numbers alone won't show?”